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Summary.-The evolution of metastatic colorectal cancer in patients who have
had surgical treatment for a primary lesion was studied in relation to the progressive
changes in the blood levels of carcinoenmbryonic antigen (CEA), y glutamyl trans-
peptidase (GGT) and routine liver function tests (LFTs). Involvement of the liver
could often be reliably predicted many weeks in advance of clinical diagnosis while
metastases to other sites were less likely to be detected early by this test. The
association of the extent of disease with the patterns of biochemical changes is
discussed with reference to several illustrative examples.
PRELIMINARY studies of the levels of
carcinoembryonic antigen (CEA) in the
various stages of colorectal cancer indicate
that conisiderable elevations often accom-
pany hepatic metastases (Steele et al.,
1974; Alackay et al., 1974) and serial
measuremeents of CEA may raise the
suspicioIn of metastases many months
ahead of the clinical confirmation (Sorkin
et al., 1974; Mlackay et al., 1974). On the
other hand, there is a large amount of ex-
perience of the usefulness ofliver ftunction
tests (LFTs) as a guide to the diagnosis of
hepatic metastases. It seems important
to compare the information obtained
fromn measurements of CEA with those
of other systems of surveillance and to
see if they are solely confirmatory or
complemnentary. Multiple discriminant
analyses lhave beein used to identify the
patterns of enzyme changes that are most
likely to be indicative of hepatic mneta-
stases comiipared w\ith distturbances caused
by various non-malignant liver diseases
(Aronsein, Nosslin and Phil, 1970) an(d to
group patients accordinig to the extent
of their hepatic metastases (Stilmant et
al., 1971). These analyses also provide
an estimate of the relative contribution
of the various components in a complex
series of liver function tests to dis-
criminate one disease from another. Our
initial investigations have suggested that
there may be advantages in combining
the measurement of CEA with simul-
taneous measurements in gamma glutamyl
transpeptidase (GGT); this combination
appears to aid the discrimination of
several of the different states encountered
in colorectal cancer.
We have now extended this study by
making observations oIn the changes of
CEA and of certain serum enzymes
during the evolution of metastases from
colorectal cancer, and on the pattern of
these measurements in post-operative
cancer-free patients. The object of this
studvy was to compare the results of
these various tests with a view to de-
visinlg a sensitive system for the earlier
detectioii of metastases and monitoriing
their response to therapy.THE EARLY DIAGNOSIS OF METASTATIC COLORECTAL CANCER
PATIENTS AND METHODS
The patients were attending hospitals in
the West and East Ridings of Yorkshire; 10
consultant surgeons have contributed cases
to this study. There are, at present, over
500 patients under surveillance; they also
form part of the MRC-DHSS carcino-
embryonic antigen trial. They can be
divided into two major groups, (i) those in
whom surveillance tests began before surgery
(cases presenting after June 1972) and (ii)
patients who had a variable disease-free
interval of one to several years before they
were entered into the trial. In this series,
there are 18 patients with hepatic metastases
and 11 with advanced disease apparently
not involving the liver, confirmed at the
time of laparotomy for treatment of the
primary tumour. A further 14 patients
have developed clinically demonstrable meta-
stases while under surveillance, 2-18 months
after excision of their primary tumour. In
addition, there are 39 patients with rising
CEA and/or GGT levels who have not, as
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FIG. 1. CEA values in patients with hepatic
metastases. 0 * diagnosis of met-
astases made at laparotomy or confirmed
clinically. *-- -- - no clinical signs of
metastases. Patient No. 10 commenced
surveillance 80 weeks after excision of
primary.
yet, been confirmed as having metastases;
these values have been abnormal for at least
3 months.
Nineteen patients who have received
chemotherapy have been excluded from
this series as both the CEA and serum
enzyme values have been observed to alter
after therapy with 1-(2-chloroethyl)-3-(4-
methyl-cyclohexyl)-1-nitrosourea (MeCCNU)
and 5-fluorouracil (Skarin et al., 1974).
Other than the measurement of the
enzyme and CEA levels, these patients have
not been subjected to any special investiga-
tions apart from those requested by the
surgeons. Liver scintiscans have been made
only when there were clinical reasons for
ordering the test. The frequency of out-
patient visits was determined by the surgeon
in charge; whenever possible the screening
tests were made at 6-monthly intervals and
at any intervening visits to hospital. The
diagnosis of metastases during surveillance
was based on routine examination by skilled
clinicians and, with one exception of hepato-
megaly which eventually was shown to be
due to metastases, the subsequent evolution
of the disease showed that their diagnoses
were correct.
The assay of CEA was as described by
Laurence et al. (1972), the upper limit of
normal being 12-5 ng/ml in our laboratory.
GGT was measured as described previously
(Steele et al., 1974).
Alkaline phosphatase was determined by
thep-nitrophenylphosphate methodofBessey,
Lowry and Brock (1946). Leucine amino-
peptidase was determined by the method of
Willig et al. (1967) with L-leucine-p-nitro-
anilide as substrate.
RESULTS
The rates of increase of CEA in
patients with hepatic metastases are
shown in Fig. 1. In some patients the
diagnosis was established at laparotomy,
in others during the surveillance. The
rates of change of GGT in these patients
are shown in Fig. 2. It will be seen that
both CEA and GGT can be raised con-
siderably for several weeks before the
confirmation of the diagnosis clinically.
Both these measurements tend to in-
crease progressively as the amount of
tumour tissue in the liver expands.
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FIG. 2.-GGT values in the patients shown
in Fig. 1. * = AP or LAP raised above
their discriminant levels, 80 and 60 i.u./l
respectively, 0
- 0 = no clinical signs
of metastases.
TABLE.-Distribution of Patients with
Moderately Increased CEA (20-100
ng/ml) According to their Serum GGT
Levels
GGT i.u./l
<30
>30 <100
>100
CEA (ng/ml
A
20-40 41-100
35/59 12/29
24/59 11/29
0/59 6/29
This Table includes data from 20 patients who
have not yet been confirmed to have metastatic
cancer. Observations made 3 or more months
after resection of primary tumour.
aminopeptidase are considerably less sensi-
tive indicators than CEA or GGT in the
majority of the patients under surveil-
lance. The changes in AP and LAP
levels showed a reasonable correlation
with one another (r - 0.77), but by the
time that AP or LAP was raised, as
defined by being above their normal mean
±2 s.d.; 80 i.u./l for AP and 60 i.u./l
for LAP, the GGT had usually been
elevated above its discriminant level
(30 i.u./l) for several weeks.
The levels of changes in GGT that
have been observed in post-operative
patients with rises ofCEA up to 100 ng/ml
are shown in the Table. Overall, it will
be seen that only 46% showed an eleva-
tion of GGT above 30 i.u. In 13 of the
whole series of patients under surveillance
a rise of GGT preceded a rise of CEA.
In a similar number of patients there
was a transient rise of GGT that was not
associated with any eventual elevation
ofCEA; this alteration ofenzyme activity
was unrelated to metastatic cancer.
The patterns of changes of levels of
CEA and enzymes in the blood ofpatients
with metastatic cancer are best seen in
3 illustrative cases.
C.M.: A 67-year old male presented with
weight loss, diarrhoea and an enlarged
liver in December 1972. Laboratory in-
vestigations showed abnormal liver function
tests: Bilirubin 0 4 mg/100 ml, AP 94 i.u./l,
serum glutamic oxaloacetic transaminase
(SGOT) 22 i.u./l, serum glutamic pyruvic
transaminase (SGPT) 12i.u./l. TheCEA was
700 ng/ml, GGT 115 i.u./1 and LAP 56
i.u./l. At laparotomy for excision of a
carcinoma of the rectosigmoid, the liver was
found to contain extensive metastases.
Apart from a small fall of CEA following
surgery, the CEA, GGT and LAP continued
to rise. He became jaundiced in September
1973 and died in November 1973 (Fig. 3).
A.H.: A 78-year old male presented with
blood loss per rectum and a mass in the
right iliac fossa. The pre-operative liver
function tests were within normal limits:
bilirubin 0.1 mg/100 ml, AP 56 i.u./l, SGOT
8 i.u./l, SPGT 4 i.u./l. In November 1972 he
had a sigmoid colectomyfor a Dukes' C carci-
noma which was considered to be a successful
resection. Surveillance was commenced 25
weeks after resection at which time his
CEA was 110 ng/ml, but the GGT and LAP
were within normal limits. Both the CEA
and GGT showed a near exponential rise.
Hepatic metastases were confirmed by liver
scintiscan 30 weeks after starting the sur-
veillance. Routine LFTs at this time showed
a bilirubin of 0-2 mg/100 ml, AP 346 i.u./l,
SGOT 22 i.u./l and SGPT 8 i.u./l (Fig. 4).
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FIG. 3.-Progress of a patient presenting
withmetastases oftheliver andperitoneum;
note the transient fall of CEA after excision
of the primary tumour.
H.M.: A 56-year old female underwent
an extended hemicolectomy for a Dukes'
C2 carcinoma of the splenic flexure in
November 1972. Surveillance began 6 weeks
after surgery, since when there has been a
slow increase of GGT. In November 1973
she was unwell, anaemic, the ESR was
raised and vague shadows appeared in her
chest x-ray which were finally confirmed to
be metastases in February 1974. Clinical
examination of the abdomen at that time
was normal. The LAP was within normal
limits throughout this illness (Fig. 5).
The illustrative cases and the data in
the Table indicate that an elevated GGT
will be encountered in about half the
patients who are discovered to have
metastases at the time of laparotomy for
excision of their primary tumour. The
majority of patients in whom metastases
were confirmed when under surveillance
as out-patients following surgery had an
elevated GGT level.
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FIG. 4.-Progressive rise of GGT and CEA,
and late rise of LAP following a resection
of a Dukes' C tumour. Aletastases con-
firmed 55 weeks after sigmoid colectomy.
Resection of the primary tumour
when there were well established hepatic
metastases had little or no effect on the
level of CEA (Fig. 6), contrasting with
the fall of the CEA level after successful
resection of localized primary tumour
(Laurence et al., 1972). The changes
encountered in hepatic metastases can
be grouped into 3 phases: Initially, there
may be no change in any of the markers;
this is observed in some patients found
to have small metastases in the liver at
laparotomy. This is followed by a pro-
gressive rise in the CEA and GGT levels
in the blood without any disturbance
of the other liver function tests (AP,
LAP and the transaminases). Finally,
the classic liver function tests become
positive, by which time the CEA levels
may be well over 1000 ng/ml and can
reach much higher values, the highest
recorded in this series being 250,000
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Fie'I. 5. Slow evolution of the rise of CEA
and GGT in a patient eventually present-
ing with pulmonary metastases 70 weeks
after resection of a primary Dukes' C
tumour.
ng/ml. This sample has been shown to
be immunologically identical to CEA by
immunodiffusion; on a simple Ouchterlony
plate it gave a line of complete identity
with authentic colonic CEA against mono-
specific anti-colonic CEA. On the other
hand, the growth of metastatic tumour
in sites other than the liver, i.e. peri-
toneum, pelvic organs or lung, was
associated1 with an increase of the CEA
and GGT levels, usually at a slower rate
than seen in hepatic metastases and
less likely to cause a disturbance in the
AP or LAP.
DIJSCUSSION
At present the adjuncts that can be
used in association with CEA for monitor-
ing colorectal cancer are all nonspecific.
Gamma glutamyl transpeptidase is well
known to be a very sensitive indicator
of liver disease but is liable to be elevated
in a variety of other diseases not directly
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FIG,. 6.--Changes in CEA during the first
2/3 months following resection of a primary
colorectal cancer inpatients with established
hepatic metastases (0---- -0, inoperable
tumour).
affecting the liver (Boone, Routh and
Schrantz, 1974). Nevertheless, in prac-
tice we have found that when this enzyme
is measured repeatedly in the same
patient a progressive rise, accompanied
by a rise in CEA, was indicative of
metastases. Two arbitrary discriminant
levels of GGT have been used > 30 < 100
i.u./l, and > 100 i.u./l: in our series all
patients who have values > 100 i.u./l
within 2 years of excision of a primary
colorectal cancer have developed meta-
stases. This may be a chance finding
but so far we have not encountered
patients suffering from other diseases
that could confuse the interpretation of
the significance of the raised GGT level.
The adoption of this high discriminant
value mirrors the same caution in the
adoption of 40 ng/ml as a discriminant
for CEA, when the normal value is
< 12-5 ng/ml (Mackay et al., 1974).
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There is a great variety of serum
enzymes that have been reported to be
increased in cancer (see review by
Schwartz, 1973). Some are well known
to be elevated in liver disease and form
the basis of standard liver function tests.
It seems that alkaline phosphatase and
leucine aminopeptidase are raised in cases
of well established metastases. Prelimin-
ary studies of 5' nucleotidase (unpublished
results) suggest that as a monitor of
colorectal cancer, its sensitivity lies be-
tween GGT and AP. The use of a
battery of enzymes enables the progress
of hepatic metastases to be followed
and gives the clinician an indication of
the extent of the disease. The wide
variation in the level of CEA produced
in hepatic metastases suggests that this
test alone does not give much indication
as to how the metastases are progressing.
The reason for the very high levels of
CEA in the blood in some patients is
unknown; it could be due to decreased
degradation of CEA or there is the
possibility that the hepatic cells may
themselves be contributing to the plasma
CEA as the result of an inductive stimulus
for CEA production receiVed from con-
tiguous cancer cells.
Such a battery of tests may be very
important when attempting to follow
the response to chemotherapy and when
trying to sort out the direct effects of the
agent upon an enzyme system compared
with the effects resulting from an improve-
ment of liver function.
There is still a need for improved
methods for detecting metastases not
involving the liver. One possibility lies
in detecting enzyme markers that are a
characteristic feature of the primary
tumour, in the hope that they might
return when the patient develops a
metastasis. Muramidase (lysozyme) may
act in this way; our present data suggest
that about 5000 of the patients with
primary tumours have elevated serum
muramidase levels which fall to normal
when the tumour is excised (Cooper et
al., 1974).
Elevations of muramidase are also
seen in some patients with hepatic or
pelvic metastases; as yet we are uncertain
whether such patients had a raised mur-
amidase at the time they first presented
with a primary.
The data from the surveillance study
indicate that GGT and standard LFTs
have a place with CEA in the monitoring
system. LFTs should be carried out if
the GGT exceeds 100 i.u./l or the CEA
500 ng/ml. There is still a pressing
need to obtain an improved test system
for the detection and monitoring of early
pelvic and peritoneal tumours as these
are often the target for adjuvant chemo-
therapy for minimal residual disease.
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